ProNeurogen

ProNeurogen is a clinical-stage biopharmaceutical company developing novel peptide-based therapeutics to treat vascular dementia, mixed dementia, and chronic pain. The company targets the root cause of vascular dementia at the vascular level to preserve cognitive function. ProNeurogen has presented at neuroscience and investor forums focused on innovative CNS therapies.